Life Sciences & Biotechnology
Title : | Evaluation of Biochemical, Pharmacological characterization of preclinical purity, safety and potency of Paris polyphylla, an ethnomedicinal plant from Arunachal Himalayas against breast cancer |
Area of research : | Life Sciences & Biotechnology |
Principal Investigator : | Dr. Pallabi Kalita Hui, National Institute Of Technology (NIT) Arunachal Pradesh |
Timeline Start Year : | 2022 |
Timeline End Year : | 2025 |
Contact info : | pallabikalita@nitap.ac.in |
Equipments : | Power Backup (3 KVA)
UPGRADATION OF EXISTING HPLC SYSTEM |
Details
Executive Summary : | As per the recent report published by The Lancet’s Globscan (2018), 18.6 million people are diagnosed with cancer whereas 9.6 million people die annually due to cancer all over the world, and further estimates that the breast cancer incidence which is most common is likely to be doubled by 2030. As per the ICMR-National Cancer Registry Report (2012 – 2014), breast cancer is one of the leading causes of cancer deaths among women in the North Eastern India. There is an opportunity for exploring novel phytotherapeutic agents from ethnopharmacologically claimed traditional medicinal plants found in the NE Region of India for prevention and treatment of cancer and oxidative stress. Critical review of literature revealed that the Paris polyphylla (Fam: Melanthiaceae), which is locally known as Dotala or Mutum Enge among the indigenous tribes of Arunachal Pradesh in the Eastern Himalaya, namely, the Nyishi, Monpa and Adi tribes as anti-fatigue, anti-proliferative, wound healing, anti-ulcer, rejuvenating agent and antidote for snake and insect poison. The dried rhizome of Paris polyphylla are also reported to be used in Traditional Chinese Medicine for treatment of inflammation, cancer and traumatic bleedings, and its mode of action is known for only a few cancer cell lines. However, review of literature revealed that the Paris polyphylla landraces and its varieties found in the Indian Himalayan region are yet to be authenticated for its pharmacognostic features, phytoconstituents, pharmacological activities including the anti-cancer properties. This preliminary study of the rhizome of Paris polyphylla collected from Arunachal Himalayan region of India showed that the ethanolic extract of this plant inhibit the growth of MDA-MB-231 breast cancer cells and other cancer types (GI50≤10μg/ml) (Debmalya et al., 2021). However, the purity (active components), safety and the efficacy with the underlying mechanism are yet to be studied in details. |
Total Budget (INR): | 47,47,732 |
Organizations involved